Engineered immune cells take on lupus in early trial

NCT ID NCT06222853

Ongoing Disease control Sponsor: The Children's Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new treatment for people with refractory systemic lupus erythematosus, a severe form of lupus that doesn't improve with standard medicines. The treatment uses the patient's own immune cells, modified to target and attack faulty immune cells that drive the disease. The main goal is to check safety, but researchers will also look for signs that the treatment can reduce lupus activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-CD19 CAR-T cells
What this could lead to: If successful, this could point toward a new treatment option for people with severe lupus that hasn't responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 22 participants, so results may not apply broadly. CAR-T therapy carries risks like cytokine release syndrome and neurotoxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CAR-T CELL THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CAR-T CELL THERAPY SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Children's Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.